Avirmax, Inc.
PrivateLast Round
Series A
Nov 12, 2019
Total Funding Raised
$3M
Company Overview
Avirmax, Inc. operates in Healthcare & Life Sciences and is based in Hayward, California. Its latest recorded funding round was a Series A round in November 2019.
Avirmax, Inc. is a biotechnology company that develops AAV-mediated gene therapies for ocular diseases and provides contract development and manufacturing (CDMO) services for viral vectors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avirmax, Inc. Comparables
Compare Avirmax, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ascend Advanced Therapies | 85% | |
| PackGene Biotech | 84% | |
| VectorBuilder | 76% |
For institutional investors. Book with your work email.
Avirmax, Inc. Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Avirmax, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bencao Capital | Series A |
| Kaitai Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2019
$3M round with Bencao Capital and Kaitai Capital.
For institutional investors. Book with your work email.
Avirmax, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Avirmax, Inc.'s valuation, stock price, and market status.
Is Avirmax, Inc. a public or private company?
Avirmax, Inc. is a private company.
What is the current stock price of Avirmax, Inc.?
Avirmax, Inc. is a private company, so its shares have no public market price. Caplight tracks Avirmax, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Avirmax, Inc. worth (valuation)?
Valuation information for Avirmax, Inc. is not publicly available.
Can I buy Avirmax, Inc. stock?
Avirmax, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Avirmax, Inc.'s last funding round?
Avirmax, Inc.'s most recent funding round was Series A on November 12, 2019.
Who are the main investors in Avirmax, Inc.?
Key investors in Avirmax, Inc. include Bencao Capital, Kaitai Capital.
Will Avirmax, Inc. IPO soon?
No public IPO plans have been announced for Avirmax, Inc..
How can I track Avirmax, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Avirmax, Inc.'s shares on secondary markets.